Adjuvant Auger Electron-Emitting Radioimmunotherapy with [
Auger electrons
epidermal growth factor receptors (EGFR)
indium-111
panitumumab
triple-negative breast cancer (TNBC)
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
04 Dec 2023
04 Dec 2023
Historique:
medline:
5
12
2023
pubmed:
20
11
2023
entrez:
20
11
2023
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC) has a high risk for recurrence and metastasis. We studied the effectiveness of Auger electron (AE) radioimmunotherapy (RIT) with antiepidermal growth factor receptor (EGFR) panitumumab conjugated with DOTA complexed to
Identifiants
pubmed: 37983089
doi: 10.1021/acs.molpharmaceut.3c00780
doi:
Substances chimiques
Panitumumab
6A901E312A
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1HTE449DGZ
ErbB Receptors
EC 2.7.10.1
Indium-111
E9NGC49E0T
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM